thalidomide has been researched along with Paraproteinemias in 60 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Paraproteinemias: A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome, with an additional 48-week open-label safety study." | 9.20 | Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. ( Hanaoka, H; Ikeda, S; Kanda, T; Katayama, K; Kikuchi, S; Kira, J; Kohara, N; Kusunoki, S; Kuwabara, S; Misawa, S; Nakashima, I; Nishizawa, M; Sato, Y; Sobue, G; Watanabe, O; Yabe, I, 2015) |
| " Here we report a case of severe ischemic cholangitis in a patient with multiple myeloma receiving chemotherapy with melphalan, prednisone, and lenalidomide." | 7.75 | Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. ( Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC, 2009) |
| "The expression of key angiogenic genes was studied in bone marrow endothelial cells (ECs) of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies unattributed/unassociated (MG[u]), diffuse large B-cell non-Hodgkin's lymphoma, in a Kaposi's sarcoma (KS) cell line, and in healthy human umbilical vein ECs (HUVECs) following exposure to therapeutic doses of thalidomide." | 7.73 | Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. ( Bicciato, S; Corradini, P; Dammacco, F; Di Pietro, G; Mattioli, M; Montefusco, V; Neri, A; Nico, B; Ribatti, D; Scavelli, C; Vacca, A, 2005) |
| "Thalidomide is an effective therapy for multiple myeloma, although its mechanisms of action remain unclear." | 6.71 | Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. ( Berk, JL; Choufani, EB; Dember, LM; Falk, RH; Fennessey, S; Finn, KT; O'Hara, C; Sanchorawala, V; Seldin, DC; Skinner, M; Wiesman, JF; Wright, DG, 2003) |
| "Lenalidomide can be a good treatment option for AL amyloidosis in HIV-infected patients on antiretroviral therapy." | 5.46 | Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient. ( Cook, M; Denman, J; Manavi, K, 2017) |
| "Scleromyxedema is a generalized, papular, and sclerodermoid form of lichen myxedematosus associated with monoclonal gammopathy and systemic changes." | 5.32 | Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. ( Cocuroccia, B; Girolomoni, G; Gisondi, P; Gubinelli, E; Jorizzo, JL; Sansbury, JC, 2004) |
| "The Japanese POEMS syndrome with Thalidomide (J-POST) Trial is a phase II/III multicentre, double-blinded, randomised, controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome, with an additional 48-week open-label safety study." | 5.20 | Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial. ( Hanaoka, H; Ikeda, S; Kanda, T; Katayama, K; Kikuchi, S; Kira, J; Kohara, N; Kusunoki, S; Kuwabara, S; Misawa, S; Nakashima, I; Nishizawa, M; Sato, Y; Sobue, G; Watanabe, O; Yabe, I, 2015) |
| "In 1999, investigators reported promising results of a phase II study of thalidomide in patients with resistant multiple myeloma (MM)." | 4.82 | Treatment of plasma cell dyscrasias with thalidomide and its derivatives. ( Anagnostopoulos, A; Dimopoulos, MA; Weber, D, 2003) |
| " Here we report a case of severe ischemic cholangitis in a patient with multiple myeloma receiving chemotherapy with melphalan, prednisone, and lenalidomide." | 3.75 | Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. ( Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC, 2009) |
| "Azotemia associated with the use of lenalidomide, a new and effective therapy for multiple myeloma, has not been reported in patients with multiple myeloma." | 3.74 | Azotemia associated with use of lenalidomide in plasma cell dyscrasias. ( Batts, ED; Hegerfeldt, Y; Lazarus, HM; Sanchorawala, V, 2008) |
| "The expression of key angiogenic genes was studied in bone marrow endothelial cells (ECs) of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies unattributed/unassociated (MG[u]), diffuse large B-cell non-Hodgkin's lymphoma, in a Kaposi's sarcoma (KS) cell line, and in healthy human umbilical vein ECs (HUVECs) following exposure to therapeutic doses of thalidomide." | 3.73 | Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. ( Bicciato, S; Corradini, P; Dammacco, F; Di Pietro, G; Mattioli, M; Montefusco, V; Neri, A; Nico, B; Ribatti, D; Scavelli, C; Vacca, A, 2005) |
| "Venous thromboembolic disease (VTD) is a recently recognized complication of thalidomide in combination therapy for patients with multiple myeloma (MM)." | 3.72 | Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. ( Cameron, MG; Deitcher, SR; Hussein, MA; Kattke-Marchant, K; Rybicki, L; Srkalovic, G, 2004) |
| "Thalidomide is an effective therapy for multiple myeloma, although its mechanisms of action remain unclear." | 2.71 | Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. ( Berk, JL; Choufani, EB; Dember, LM; Falk, RH; Fennessey, S; Finn, KT; O'Hara, C; Sanchorawala, V; Seldin, DC; Skinner, M; Wiesman, JF; Wright, DG, 2003) |
| "Systematic search for monoclonal gammopathy by immunofixation and serum free light chains is very useful for the management of progressive peripheral neuropathies of unknown origin." | 2.47 | [New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome]. ( Adams, D; Bourhis, JH; Lacroix, C; Lozeron, P; Ribrag, V; Theaudin, M, 2011) |
| "Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties." | 2.44 | Treatment of plasma cell dyscrasias with lenalidomide. ( Dimopoulos, MA; Kastritis, E; Rajkumar, SV, 2008) |
| "Scleromyxedema is a rare idiopathic fibromucinous disorder characterized by a generalized papular and sclerodermoid cutaneous eruption." | 1.72 | Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins. ( Chen, QY; Wang, SS; Xiang, LH, 2022) |
| "The term monoclonal gammopathy of renal significance (MGRS) was introduced in 2012 to emphasize kidney lesions in monoclonal gammopathy patients." | 1.51 | Bortezomib-Based Chemotherapy with Autologous Stem Cell Transplantation for Monoclonal Gammopathy of Renal Significance: A Case Report and Literature Review. ( Huang, J; Su, H; Sun, C; Xiong, J; Zhang, C, 2019) |
| "Lenalidomide can be a good treatment option for AL amyloidosis in HIV-infected patients on antiretroviral therapy." | 1.46 | Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient. ( Cook, M; Denman, J; Manavi, K, 2017) |
| "Lenalidomide is a potential treatment option for refractory bleeding in AVWS secondary to MG." | 1.43 | Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. ( Brophy, TM; Browne, PV; Hayden, PJ; Lavin, M; O'Connell, N; O'Donnell, JS; O'Sullivan, JM; Rawley, O; Ryan, K, 2016) |
| "Treatment with thalidomide has proved to be effective in the management of these patients." | 1.40 | Scleromyxedema without paraproteinemia. ( Abarzúa, AA; Giesen, LF; González, SB; Sandoval, MO, 2014) |
| "The scleromyxedema is a rare condition characterized by hyperproliferation of fibroblasts with increased dermal deposition of mucin and frequently associated with monoclonal gammopathy of undetermined significance." | 1.39 | [Response to thalidomide in scleromyxedema]. ( Caballero Escuti, G; Kurpis, M; Pascualini, MF; Ruiz Lascano, A; Valente, E, 2013) |
| "The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide." | 1.37 | History of multiple myeloma. ( Kyle, RA; Steensma, DP, 2011) |
| "Thalidomide was introduced but was discontinued after 2 months due to side effects." | 1.36 | [Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema]. ( Cardot-Leccia, N; Lacour, JP; Ortonne, JP; Passeron, T; Perrin, C; Sillard, L, 2010) |
| "Scleromyxedema is a generalized, papular, and sclerodermoid form of lichen myxedematosus associated with monoclonal gammopathy and systemic changes." | 1.32 | Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. ( Cocuroccia, B; Girolomoni, G; Gisondi, P; Gubinelli, E; Jorizzo, JL; Sansbury, JC, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (28.33) | 29.6817 |
| 2010's | 39 (65.00) | 24.3611 |
| 2020's | 4 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, D | 1 |
| Wang, Y | 1 |
| Sun, S | 1 |
| Wang, SS | 1 |
| Chen, QY | 1 |
| Xiang, LH | 1 |
| Gau, YC | 1 |
| Hsiao, HH | 1 |
| Liu, YC | 1 |
| Yeh, TJ | 1 |
| Arbab, A | 1 |
| Saada, V | 1 |
| Cotteret, S | 1 |
| Marzac, C | 1 |
| Ghez, D | 1 |
| Denman, J | 1 |
| Manavi, K | 1 |
| Cook, M | 1 |
| Al-Mayoof, O | 1 |
| Al Sughaiyer, H | 1 |
| Abuomar, W | 1 |
| Khan, M | 1 |
| Zaidi, S | 1 |
| Sattar, S | 1 |
| Asumal, KB | 1 |
| Laribi, K | 1 |
| Alani, M | 1 |
| Lemaire, P | 1 |
| Turnbull, AMJ | 1 |
| Karmiris, E | 1 |
| Anderson, DF | 1 |
| Naddaf, E | 1 |
| Milone, M | 1 |
| Kansagra, A | 1 |
| Buadi, F | 1 |
| Kourelis, T | 1 |
| Huang, J | 1 |
| Sun, C | 1 |
| Su, H | 1 |
| Zhang, C | 1 |
| Xiong, J | 1 |
| Pascualini, MF | 1 |
| Caballero Escuti, G | 1 |
| Valente, E | 1 |
| Kurpis, M | 1 |
| Ruiz Lascano, A | 1 |
| Sánchez Quintana, A | 1 |
| Rull, PR | 1 |
| Atienza, JB | 1 |
| McDonnell, CN | 1 |
| Mesa-Gutiérrez, JC | 1 |
| Rouras-López, A | 1 |
| Amías-Lamana, V | 1 |
| Hoyos-Chacón, J | 1 |
| Cabiró-Badimón, I | 1 |
| Porta-Monnet, J | 1 |
| Abarzúa, AA | 1 |
| Giesen, LF | 1 |
| Sandoval, MO | 1 |
| González, SB | 1 |
| Mahmood, S | 1 |
| Venner, CP | 1 |
| Sachchithanantham, S | 1 |
| Lane, T | 1 |
| Rannigan, L | 1 |
| Foard, D | 1 |
| Pinney, JH | 1 |
| Gibbs, SD | 1 |
| Whelan, CJ | 1 |
| Lachmann, HJ | 1 |
| Gillmore, JD | 1 |
| Hawkins, PN | 1 |
| Wechalekar, AD | 1 |
| Gkotzamanidou, M | 2 |
| Terpos, E | 2 |
| Kastritis, E | 3 |
| Dimopoulos, MA | 4 |
| Cheng, J | 1 |
| Talamo, G | 1 |
| Malysz, J | 1 |
| Ochmann, M | 1 |
| Lamy, T | 1 |
| Loughran, TP | 1 |
| Manni, E | 1 |
| Cervadoro, E | 1 |
| Papineschi, F | 1 |
| Talbot, B | 1 |
| Wright, D | 1 |
| Basnayake, K | 1 |
| Katayama, K | 1 |
| Misawa, S | 1 |
| Sato, Y | 1 |
| Sobue, G | 1 |
| Yabe, I | 1 |
| Watanabe, O | 1 |
| Nishizawa, M | 1 |
| Kusunoki, S | 1 |
| Kikuchi, S | 1 |
| Nakashima, I | 1 |
| Ikeda, S | 1 |
| Kohara, N | 1 |
| Kanda, T | 1 |
| Kira, J | 1 |
| Hanaoka, H | 1 |
| Kuwabara, S | 1 |
| Dholaria, BR | 1 |
| Cappel, M | 1 |
| Roy, V | 1 |
| Lavin, M | 1 |
| Brophy, TM | 1 |
| Rawley, O | 1 |
| O'Sullivan, JM | 1 |
| Hayden, PJ | 1 |
| Browne, PV | 1 |
| Ryan, K | 1 |
| O'Connell, N | 1 |
| O'Donnell, JS | 1 |
| Korde, N | 1 |
| Zhang, Y | 1 |
| Loeliger, K | 1 |
| Poon, A | 1 |
| Simakova, O | 1 |
| Zingone, A | 1 |
| Costello, R | 1 |
| Childs, R | 1 |
| Noel, P | 1 |
| Silver, S | 1 |
| Kwok, M | 1 |
| Mo, C | 1 |
| Young, N | 1 |
| Landgren, O | 1 |
| Sloand, E | 1 |
| Maric, I | 1 |
| De Lazzari, M | 1 |
| Fedrigo, M | 1 |
| Migliore, F | 1 |
| Cianci, A | 1 |
| Cacciavillani, L | 1 |
| Tarantini, G | 1 |
| Giorgi, B | 1 |
| Iliceto, S | 1 |
| Thiene, G | 1 |
| Valente, M | 1 |
| Angelini, A | 1 |
| Adami, F | 1 |
| Perazzolo Marra, M | 1 |
| Cao, XX | 1 |
| Wang, T | 1 |
| Liu, YH | 1 |
| Zhou, DB | 1 |
| Li, J | 1 |
| Hogan, JJ | 1 |
| Weiss, BM | 1 |
| Rajkumar, SV | 2 |
| Weisel, KC | 1 |
| Böckeler, M | 1 |
| Bianchi, L | 1 |
| Terracciano, LM | 1 |
| Mayer, F | 1 |
| Kanz, L | 1 |
| Eby, C | 1 |
| Laimer, M | 1 |
| Namberger, K | 1 |
| Massone, C | 1 |
| Koller, J | 1 |
| Emberger, M | 1 |
| Pleyer, L | 1 |
| Hintner, H | 1 |
| Greil, R | 1 |
| Sillard, L | 1 |
| Passeron, T | 1 |
| Cardot-Leccia, N | 1 |
| Perrin, C | 1 |
| Lacour, JP | 1 |
| Ortonne, JP | 1 |
| Arellano-Rodrigo, E | 1 |
| Liedtke, M | 1 |
| Medeiros, BC | 1 |
| Le Moigne, M | 1 |
| Mazereeuw-Hautier, J | 1 |
| Bonnetblanc, JM | 1 |
| Astudillo, L | 1 |
| D'Incan, M | 1 |
| Bessis, D | 1 |
| Thomas, L | 1 |
| Debarbieux, S | 1 |
| Ammoury, A | 1 |
| Lamant, L | 1 |
| Paul, C | 1 |
| Adams, D | 1 |
| Lozeron, P | 1 |
| Theaudin, M | 1 |
| Ribrag, V | 1 |
| Bourhis, JH | 1 |
| Lacroix, C | 1 |
| Desport, E | 1 |
| Moumas, E | 1 |
| Abraham, J | 1 |
| Delbès, S | 1 |
| Lacotte-Thierry, L | 1 |
| Touchard, G | 1 |
| Fermand, JP | 1 |
| Bridoux, F | 1 |
| Jaccard, A | 1 |
| Kyle, RA | 3 |
| Steensma, DP | 1 |
| Efebera, Y | 1 |
| Blanchard, E | 1 |
| Allam, C | 1 |
| Han, A | 1 |
| Lee, S | 1 |
| Munshi, N | 1 |
| do Prado, AD | 1 |
| Schmoeller, D | 1 |
| Bisi, MC | 1 |
| Piovesan, DM | 1 |
| Dias, FS | 1 |
| Staub, HL | 1 |
| Neuber, B | 1 |
| Herth, I | 1 |
| Tolliver, C | 1 |
| Schoenland, S | 1 |
| Hegenbart, U | 1 |
| Hose, D | 1 |
| Witzens-Harig, M | 1 |
| Ho, AD | 1 |
| Goldschmidt, H | 1 |
| Klein, B | 1 |
| Hundemer, M | 1 |
| Larsen, LH | 1 |
| Lund, T | 1 |
| Vilholm, OJ | 1 |
| Plesner, T | 1 |
| Zagouri, F | 1 |
| Roussou, M | 1 |
| Koureas, A | 1 |
| Tsokou, E | 1 |
| Migkou, M | 1 |
| Gavriatopoulou, M | 1 |
| Nikitas, N | 1 |
| Alexander, MP | 1 |
| Nasr, SH | 1 |
| Watson, DC | 1 |
| Méndez, GP | 1 |
| Rennke, HG | 1 |
| Hu, X | 1 |
| Liu, J | 1 |
| Bai, C | 1 |
| Wang, J | 1 |
| Song, X | 1 |
| Jimenez-Zepeda, VH | 1 |
| Vajpeyi, R | 1 |
| John, R | 1 |
| Trudel, S | 1 |
| Guarenti, I | 1 |
| Sebastiani, V | 1 |
| Pinto, G | 1 |
| de Souza, PR | 1 |
| de Almeida, H | 1 |
| Shuttleworth, GN | 1 |
| Cook, SD | 1 |
| Ropner, JE | 1 |
| Anderson, KC | 1 |
| Seldin, DC | 1 |
| Choufani, EB | 1 |
| Dember, LM | 1 |
| Wiesman, JF | 1 |
| Berk, JL | 1 |
| Falk, RH | 1 |
| O'Hara, C | 1 |
| Fennessey, S | 1 |
| Finn, KT | 1 |
| Wright, DG | 1 |
| Skinner, M | 1 |
| Sanchorawala, V | 2 |
| Bladé, J | 1 |
| Rosiñol, L | 1 |
| Anagnostopoulos, A | 1 |
| Weber, D | 1 |
| Sansbury, JC | 1 |
| Cocuroccia, B | 1 |
| Jorizzo, JL | 1 |
| Gubinelli, E | 1 |
| Gisondi, P | 1 |
| Girolomoni, G | 1 |
| Srkalovic, G | 1 |
| Cameron, MG | 1 |
| Rybicki, L | 1 |
| Deitcher, SR | 1 |
| Kattke-Marchant, K | 1 |
| Hussein, MA | 1 |
| Vacca, A | 1 |
| Scavelli, C | 1 |
| Montefusco, V | 1 |
| Di Pietro, G | 1 |
| Neri, A | 1 |
| Mattioli, M | 1 |
| Bicciato, S | 1 |
| Nico, B | 1 |
| Ribatti, D | 1 |
| Dammacco, F | 1 |
| Corradini, P | 1 |
| Zangari, M | 1 |
| Elice, F | 1 |
| Fink, L | 1 |
| Tricot, G | 1 |
| Patil, S | 1 |
| Schwarer, A | 1 |
| McLean, C | 1 |
| Batts, ED | 1 |
| Hegerfeldt, Y | 1 |
| Lazarus, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients[NCT00396045] | Phase 1/Phase 2 | 54 participants | Interventional | 2005-01-31 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients[NCT02384083] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance[NCT01647165] | Phase 2 | 0 participants (Actual) | Interventional | 2012-07-11 | Withdrawn | ||
| Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study[NCT01675141] | Phase 2 | 11 participants (Actual) | Interventional | 2012-08-20 | Terminated (stopped due to Original investigator left the NIH and the primary outcome was not reached) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of response is defined as time from response to disease progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | Months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
Here is the number of serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01675141)
Timeframe: 37 months and 12 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | 11 |
PFS is defined as the time from study entry until progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be >10mg/dl. (NCT01675141)
Timeframe: participants were followed for the duration of their treatment, an average of 2 years
| Intervention | months (Median) |
|---|---|
| Lenalidomide Maintenance Therapy for Multiple Myeloma | NA |
12 reviews available for thalidomide and Paraproteinemias
| Article | Year |
|---|---|
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophospha | 2016 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bor | 2008 |
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.
Topics: Blood Coagulation Disorders; Blood Platelet Disorders; Boronic Acids; Bortezomib; Hemorrhage; Humans | 2009 |
Plasma cell leukemia: concepts and management.
Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenali | 2010 |
[New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome].
Topics: Amyloid; Amyloid Neuropathies; Biomarkers; Biopsy; Castleman Disease; Combined Modality Therapy; Dru | 2011 |
[Current treatment of AL amyloidosis].
Topics: Amyloid; Amyloidosis; Biomarkers; Boronic Acids; Bortezomib; Cardiomyopathies; Consensus Development | 2011 |
Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature.
Topics: Aged; Dexamethasone; Humans; Immunosuppressive Agents; Male; Necrobiotic Xanthogranuloma; Paraprotei | 2011 |
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cuti | 2011 |
Multiple myeloma: how far have we come?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diagnosis, Differential; Humans; Multip | 2003 |
Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
Topics: Adjuvants, Immunologic; Dexamethasone; Drug Therapy, Combination; Forecasting; Humans; Multiple Myel | 2003 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Hu | 2004 |
Thrombosis in multiple myeloma.
Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Cytokines | 2007 |
2 trials available for thalidomide and Paraproteinemias
| Article | Year |
|---|---|
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Clinical Protocols; Double-Blind Method; Female; Hematologic Agents; Humans; Japan; Male; Mul | 2015 |
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.
Topics: Adult; Aged; Amyloidosis; Female; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Mal | 2003 |
46 other studies available for thalidomide and Paraproteinemias
| Article | Year |
|---|---|
Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone.
Topics: Biopsy; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Glucocorticoids; Humans; | 2021 |
Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Topics: Exanthema; Female; Humans; Immunoglobulins, Intravenous; Middle Aged; Paraproteinemias; Rare Disease | 2022 |
Case report of coexistence of myeloproliferative neoplasms and multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bortezomib; Dexameth | 2020 |
Plasma cell dedifferentiation in refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Dedifferentiation | 2021 |
Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; HI | 2017 |
POEMS syndrome: a rare cause of exudative ascites and chronic peripheral neuropathy.
Topics: Adult; Ascites; Dexamethasone; Humans; Lenalidomide; Male; Myeloma Proteins; Paraproteinemias; Perip | 2017 |
An Adult with Polyneuropathy and Hypogonadism due to Poems Syndrome.
Topics: Adult; Dexamethasone; Female; Humans; Hypogonadism; Melphalan; Paraproteinemias; POEMS Syndrome; Pol | 2017 |
IgM k multiple myeloma with monoclonal surface immunoglobulin expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bortezomib; Dexamethasone; Female | 2018 |
Active IgGκ Multiple Myeloma Presenting With Crystalline Keratopathy.
Topics: Aged; Antineoplastic Agents; Bortezomib; Corneal Diseases; Dexamethasone; Drug Therapy, Combination; | 2018 |
Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosu | 2019 |
Bortezomib-Based Chemotherapy with Autologous Stem Cell Transplantation for Monoclonal Gammopathy of Renal Significance: A Case Report and Literature Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem | 2019 |
[Response to thalidomide in scleromyxedema].
Topics: Female; Humans; Immunosuppressive Agents; Middle Aged; Paraproteinemias; Scleromyxedema; Thalidomide | 2013 |
Renal transplant in plasma cell dyscrasias with lenalidomide treatment after autologous stem cell transplantation.
Topics: Adult; Female; Humans; Immunologic Factors; Immunosuppressive Agents; Kidney Diseases; Kidney Transp | 2013 |
[Crystalline keratopathy due to kappa chains in a monoclonal gammopathy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Combined Modality Therapy; Corn | 2013 |
Scleromyxedema without paraproteinemia.
Topics: Adolescent; Humans; Immunosuppressive Agents; Male; Paraproteinemias; Scleromyxedema; Thalidomide | 2014 |
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combinati | 2014 |
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Fatig | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto | 2014 |
Case of erythema elevatum diutinum associated with IgA paraproteinemia successfully controlled with thalidomide and plasma exchange.
Topics: Aged, 80 and over; Humans; Immunoglobulin A; Immunosuppressive Agents; Male; Paraproteinemias; Plasm | 2015 |
The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diagnosi | 2014 |
Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Drug Therapy, Combination; | 2016 |
Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Hemorrhage; Humans; Lenalidomide; Male; Middle A | 2016 |
Monoclonal gammopathy-associated pure red cell aplasia.
Topics: Adult; Aged; Bone Marrow; Dexamethasone; Diagnosis, Differential; Female; Humans; Immunoglobulins; L | 2016 |
Nonamyloidotic Light Chain Cardiomyopathy: The Arrhythmogenic Magnetic Resonance Pattern.
Topics: Bortezomib; Cardiomyopathies; Combined Modality Therapy; Defibrillators, Implantable; Dexamethasone; | 2016 |
Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Immunogl | 2016 |
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis; Hepatic Artery; Humans; Immunoglo | 2009 |
Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.
Topics: Antineoplastic Agents; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Human | 2009 |
[Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema].
Topics: Adrenal Cortex Hormones; Drug Resistance; Female; Humans; Immunoglobulin G; Immunoglobulin lambda-Ch | 2010 |
Case 23-2010: Unusual paraprotein effects in MGUS--treat or not?
Topics: Antineoplastic Agents; Humans; Kidney Diseases; Lenalidomide; Lymphangiectasis; Lymphangioma, Cystic | 2010 |
[Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study].
Topics: Adrenal Cortex Hormones; Adult; Aged; Biopsy; Combined Modality Therapy; Diagnosis, Differential; Fe | 2010 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, | 2011 |
Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis?
Topics: Brain Diseases; Coma; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Myeloablative | 2012 |
Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Cells, Cultured; Cytokines; Down-Regulation; Epitopes, T- | 2011 |
Anti-myelin associated glycoprotein neuropathy responding to lenalidomide.
Topics: Aged; Antineoplastic Agents; Demyelinating Diseases; Humans; Immunoglobulin M; Lenalidomide; Male; M | 2011 |
Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.
Topics: Aged; Animals; Female; Humans; Immunologic Factors; Lenalidomide; Male; Mice; Middle Aged; Paraprote | 2011 |
Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; | 2012 |
Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Gastrointestinal Tract; Humans; Imm | 2012 |
Successful treatment of scleromyxedema with oral thalidomide.
Topics: Adult; Humans; Hyperpigmentation; Immunosuppressive Agents; Male; Paraproteinemias; Scleromyxedema; | 2013 |
Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Corneal Diseases; Cyclophosphamide; Doxo | 2002 |
Thalidomide: a step forward in the treatment of malignant monoclonal gammopathies.
Topics: Amyloidosis; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunosuppressive Ag | 2003 |
Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients.
Topics: Aged; Female; Humans; Lichenoid Eruptions; Male; Middle Aged; Myxedema; Paraproteinemias; Scleroderm | 2004 |
Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Female; Humans; | 2004 |
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Cells, Cultured; Culture Media | 2005 |
New strategies for MGUS and smoldering multiple myeloma.
Topics: Diphosphonates; Disease Management; Disease Progression; Drug Design; Humans; Immunoglobulin kappa-C | 2004 |
Urinary cytology in multiple myeloma.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Fat | 2008 |
Azotemia associated with use of lenalidomide in plasma cell dyscrasias.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azotemia; Dexameth | 2008 |